Sublingual  ||| S:0 E:11 ||| JJ
immunotherapy ||| S:11 E:24 ||| NN
:  ||| S:24 E:26 ||| :
administration ||| S:26 E:40 ||| NN
,  ||| S:40 E:42 ||| ,
dosages ||| S:42 E:49 ||| NN
,  ||| S:49 E:51 ||| ,
use  ||| S:51 E:55 ||| VBP
Allergen  ||| S:55 E:64 ||| JJ
extracts  ||| S:64 E:73 ||| NN
for  ||| S:73 E:77 ||| IN
sublingual  ||| S:77 E:88 ||| JJ
immunotherapy  ||| S:88 E:102 ||| NNS
( ||| S:102 E:103 ||| -LRB-
SLIT ||| S:103 E:107 ||| NNP
)  ||| S:107 E:109 ||| -RRB-
are  ||| S:109 E:113 ||| VBP
currently  ||| S:113 E:123 ||| RB
marketed  ||| S:123 E:132 ||| VBN
by  ||| S:132 E:135 ||| IN
several  ||| S:135 E:143 ||| JJ
manufacturers ||| S:143 E:156 ||| NNS
,  ||| S:156 E:158 ||| ,
with  ||| S:158 E:163 ||| IN
administration  ||| S:163 E:178 ||| NN
schedules  ||| S:178 E:188 ||| NNS
and  ||| S:188 E:192 ||| CC
amount  ||| S:192 E:199 ||| NN
of  ||| S:199 E:202 ||| IN
allergen ||| S:202 E:210 ||| NNS
( ||| S:210 E:211 ||| -LRB-
s ||| S:211 E:212 ||| LS
)  ||| S:212 E:214 ||| -RRB-
quite  ||| S:214 E:220 ||| RB
variable  ||| S:220 E:229 ||| VBN
in  ||| S:229 E:232 ||| IN
the  ||| S:232 E:236 ||| DT
different  ||| S:236 E:246 ||| JJ
products ||| S:246 E:254 ||| NNS
,  ||| S:254 E:256 ||| ,
although  ||| S:256 E:265 ||| IN
almost  ||| S:265 E:272 ||| RB
all  ||| S:272 E:276 ||| RB
are  ||| S:276 E:280 ||| VBP
standardized  ||| S:280 E:293 ||| JJ
biologically  ||| S:293 E:306 ||| NN
or  ||| S:306 E:309 ||| CC
immunologically ||| S:309 E:324 ||| NN
.  ||| S:324 E:326 ||| .
The  ||| S:326 E:330 ||| DT
allergen  ||| S:330 E:339 ||| JJ
extracts  ||| S:339 E:348 ||| NN
for  ||| S:348 E:352 ||| IN
SLIT  ||| S:352 E:357 ||| NNP
are  ||| S:357 E:361 ||| VBP
available  ||| S:361 E:371 ||| JJ
in  ||| S:371 E:374 ||| IN
two  ||| S:374 E:378 ||| CD
main  ||| S:378 E:383 ||| JJ
pharmaceutical  ||| S:383 E:398 ||| JJ
forms ||| S:398 E:403 ||| NNS
:  ||| S:403 E:405 ||| :
solution  ||| S:405 E:414 ||| NN
to  ||| S:414 E:417 ||| TO
be  ||| S:417 E:420 ||| VB
delivered  ||| S:420 E:430 ||| VBN
by  ||| S:430 E:433 ||| IN
drop-counters ||| S:433 E:446 ||| NNP
,  ||| S:446 E:448 ||| ,
pre-dosed  ||| S:448 E:458 ||| JJ
actuators  ||| S:458 E:468 ||| NNS
( ||| S:468 E:469 ||| -LRB-
mini-pumps ||| S:469 E:479 ||| NNP
)  ||| S:479 E:481 ||| -RRB-
or  ||| S:481 E:484 ||| CC
disposable  ||| S:484 E:495 ||| JJ
single-dose  ||| S:495 E:507 ||| JJ
vials ||| S:507 E:512 ||| NN
;  ||| S:512 E:514 ||| :
tablets  ||| S:514 E:522 ||| NNS
with  ||| S:522 E:527 ||| IN
appropriate  ||| S:527 E:539 ||| JJ
composition  ||| S:539 E:551 ||| NN
that  ||| S:551 E:556 ||| WDT
allows  ||| S:556 E:563 ||| VBZ
a  ||| S:563 E:565 ||| DT
slow  ||| S:565 E:570 ||| JJ
( ||| S:570 E:571 ||| -LRB-
1-2  ||| S:571 E:575 ||| CD
minutes ||| S:575 E:582 ||| NNS
)  ||| S:582 E:584 ||| -RRB-
dissolution  ||| S:584 E:596 ||| NN
in  ||| S:596 E:599 ||| IN
the  ||| S:599 E:603 ||| DT
mouth  ||| S:603 E:609 ||| NN
in  ||| S:609 E:612 ||| IN
contact  ||| S:612 E:620 ||| NN
with  ||| S:620 E:625 ||| IN
saliva ||| S:625 E:631 ||| NN
.  ||| S:631 E:633 ||| .
In  ||| S:633 E:636 ||| IN
Europe ||| S:636 E:642 ||| NNP
,  ||| S:642 E:644 ||| ,
SLIT  ||| S:644 E:649 ||| NNP
is  ||| S:649 E:652 ||| VBZ
prescribed  ||| S:652 E:663 ||| VBN
in  ||| S:663 E:666 ||| IN
general  ||| S:666 E:674 ||| JJ
for  ||| S:674 E:678 ||| IN
one  ||| S:678 E:682 ||| CD
or  ||| S:682 E:685 ||| CC
a  ||| S:685 E:687 ||| DT
few  ||| S:687 E:691 ||| JJ
allergens ||| S:691 E:700 ||| NN
,  ||| S:700 E:702 ||| ,
and  ||| S:702 E:706 ||| CC
mixtures  ||| S:706 E:715 ||| NNS
are  ||| S:715 E:719 ||| VBP
less  ||| S:719 E:724 ||| RBR
used ||| S:724 E:728 ||| VBN
,  ||| S:728 E:730 ||| ,
though  ||| S:730 E:737 ||| IN
there  ||| S:737 E:743 ||| EX
is  ||| S:743 E:746 ||| VBZ
no  ||| S:746 E:749 ||| DT
immunological  ||| S:749 E:763 ||| JJ
contraindication  ||| S:763 E:780 ||| NN
to  ||| S:780 E:783 ||| TO
give  ||| S:783 E:788 ||| VB
multiple  ||| S:788 E:797 ||| JJ
allergens ||| S:797 E:806 ||| NN
.  ||| S:806 E:808 ||| .
SLIT  ||| S:808 E:813 ||| NNP
traditionally  ||| S:813 E:827 ||| RB
involves  ||| S:827 E:836 ||| VBZ
a  ||| S:836 E:838 ||| DT
build-up  ||| S:838 E:847 ||| NN
phase  ||| S:847 E:853 ||| NN
and  ||| S:853 E:857 ||| CC
a  ||| S:857 E:859 ||| DT
maintenance  ||| S:859 E:871 ||| NN
phase  ||| S:871 E:877 ||| NN
with  ||| S:877 E:882 ||| IN
the  ||| S:882 E:886 ||| DT
top  ||| S:886 E:890 ||| JJ
dose ||| S:890 E:894 ||| NN
.  ||| S:894 E:896 ||| .
The  ||| S:896 E:900 ||| DT
build-up  ||| S:900 E:909 ||| NN
phase  ||| S:909 E:915 ||| NN
has  ||| S:915 E:919 ||| VBZ
usually  ||| S:919 E:927 ||| RB
the  ||| S:927 E:931 ||| DT
duration  ||| S:931 E:940 ||| NN
of  ||| S:940 E:943 ||| IN
4  ||| S:943 E:945 ||| CD
-  ||| S:945 E:947 ||| :
6  ||| S:947 E:949 ||| CD
weeks ||| S:949 E:954 ||| NNS
.  ||| S:954 E:956 ||| .
The  ||| S:956 E:960 ||| DT
patient  ||| S:960 E:968 ||| NN
must  ||| S:968 E:973 ||| MD
start  ||| S:973 E:979 ||| VB
with  ||| S:979 E:984 ||| IN
the  ||| S:984 E:988 ||| DT
lowest  ||| S:988 E:995 ||| JJS
concentration  ||| S:995 E:1009 ||| NN
and  ||| S:1009 E:1013 ||| CC
gradually  ||| S:1013 E:1023 ||| RB
increase ||| S:1023 E:1031 ||| VB
,  ||| S:1031 E:1033 ||| ,
using  ||| S:1033 E:1039 ||| VBG
the  ||| S:1039 E:1043 ||| DT
different  ||| S:1043 E:1053 ||| JJ
dosage  ||| S:1053 E:1060 ||| NN
preparations ||| S:1060 E:1072 ||| NNS
,  ||| S:1072 E:1074 ||| ,
until  ||| S:1074 E:1080 ||| IN
the  ||| S:1080 E:1084 ||| DT
maintenance  ||| S:1084 E:1096 ||| NN
dose  ||| S:1096 E:1101 ||| NN
is  ||| S:1101 E:1104 ||| VBZ
reached ||| S:1104 E:1111 ||| VBN
.  ||| S:1111 E:1113 ||| .
Rush  ||| S:1113 E:1118 ||| NNP
and  ||| S:1118 E:1122 ||| CC
ultra-rush  ||| S:1122 E:1133 ||| JJ
inductions  ||| S:1133 E:1144 ||| NNS
have  ||| S:1144 E:1149 ||| VBP
been  ||| S:1149 E:1154 ||| VBN
introduced ||| S:1154 E:1164 ||| VBN
,  ||| S:1164 E:1166 ||| ,
based  ||| S:1166 E:1172 ||| VBN
on  ||| S:1172 E:1175 ||| IN
the  ||| S:1175 E:1179 ||| DT
safety  ||| S:1179 E:1186 ||| NN
profile  ||| S:1186 E:1194 ||| NN
of  ||| S:1194 E:1197 ||| IN
SLIT  ||| S:1197 E:1202 ||| NNP
that  ||| S:1202 E:1207 ||| WDT
is  ||| S:1207 E:1210 ||| VBZ
very  ||| S:1210 E:1215 ||| RB
favorable ||| S:1215 E:1224 ||| JJ
.  ||| S:1224 E:1226 ||| .
For  ||| S:1226 E:1230 ||| IN
these  ||| S:1230 E:1236 ||| DT
reasons  ||| S:1236 E:1244 ||| NNS
it  ||| S:1244 E:1247 ||| PRP
has  ||| S:1247 E:1251 ||| VBZ
been  ||| S:1251 E:1256 ||| VBN
suggested  ||| S:1256 E:1266 ||| VBN
that  ||| S:1266 E:1271 ||| IN
an  ||| S:1271 E:1274 ||| DT
updosing  ||| S:1274 E:1283 ||| JJ
phase  ||| S:1283 E:1289 ||| NN
maybe  ||| S:1289 E:1295 ||| RB
even  ||| S:1295 E:1300 ||| RB
not  ||| S:1300 E:1304 ||| RB
necessary ||| S:1304 E:1313 ||| JJ
.  ||| S:1313 E:1315 ||| .
The  ||| S:1315 E:1319 ||| DT
no-updosing  ||| S:1319 E:1331 ||| JJ
approach  ||| S:1331 E:1340 ||| NN
would  ||| S:1340 E:1346 ||| MD
result  ||| S:1346 E:1353 ||| VB
in  ||| S:1353 E:1356 ||| IN
a  ||| S:1356 E:1358 ||| DT
treatment  ||| S:1358 E:1368 ||| NN
that  ||| S:1368 E:1373 ||| WDT
is  ||| S:1373 E:1376 ||| VBZ
more  ||| S:1376 E:1381 ||| RBR
patient-friendly  ||| S:1381 E:1398 ||| JJ
and  ||| S:1398 E:1402 ||| CC
convenient  ||| S:1402 E:1413 ||| JJ
to  ||| S:1413 E:1416 ||| TO
manage ||| S:1416 E:1422 ||| VB
.  ||| S:1422 E:1424 ||| .
Indeed ||| S:1424 E:1430 ||| RB
,  ||| S:1430 E:1432 ||| ,
the  ||| S:1432 E:1436 ||| DT
most  ||| S:1436 E:1441 ||| RBS
recent  ||| S:1441 E:1448 ||| JJ
randomized  ||| S:1448 E:1459 ||| JJ
trials  ||| S:1459 E:1466 ||| NNS
were  ||| S:1466 E:1471 ||| VBD
performed  ||| S:1471 E:1481 ||| VBN
with  ||| S:1481 E:1486 ||| IN
the  ||| S:1486 E:1490 ||| DT
no-updosing  ||| S:1490 E:1502 ||| JJ
regimen  ||| S:1502 E:1510 ||| NN
and  ||| S:1510 E:1514 ||| CC
their  ||| S:1514 E:1520 ||| PRP$
results  ||| S:1520 E:1528 ||| NNS
in  ||| S:1528 E:1531 ||| IN
term  ||| S:1531 E:1536 ||| NN
of  ||| S:1536 E:1539 ||| IN
safety  ||| S:1539 E:1546 ||| NN
were  ||| S:1546 E:1551 ||| VBD
as  ||| S:1551 E:1554 ||| IN
favorable  ||| S:1554 E:1564 ||| JJ
as  ||| S:1564 E:1567 ||| IN
the  ||| S:1567 E:1571 ||| DT
studies  ||| S:1571 E:1579 ||| NNS
performed  ||| S:1579 E:1589 ||| VBN
with  ||| S:1589 E:1594 ||| IN
the  ||| S:1594 E:1598 ||| DT
traditional  ||| S:1598 E:1610 ||| JJ
updosing  ||| S:1610 E:1619 ||| JJ
approach ||| S:1619 E:1627 ||| NN
.  ||| S:1627 E:1629 ||| .
The  ||| S:1629 E:1633 ||| DT
currently  ||| S:1633 E:1643 ||| RB
recommended  ||| S:1643 E:1655 ||| VBN
duration  ||| S:1655 E:1664 ||| NN
of  ||| S:1664 E:1667 ||| IN
SLIT  ||| S:1667 E:1672 ||| NNP
is  ||| S:1672 E:1675 ||| VBZ
comprised  ||| S:1675 E:1685 ||| VBN
between  ||| S:1685 E:1693 ||| IN
3  ||| S:1693 E:1695 ||| CD
and  ||| S:1695 E:1699 ||| CC
4  ||| S:1699 E:1701 ||| CD
years  ||| S:1701 E:1707 ||| NNS
depending  ||| S:1707 E:1717 ||| VBG
on  ||| S:1717 E:1720 ||| IN
the  ||| S:1720 E:1724 ||| DT
clinical  ||| S:1724 E:1733 ||| JJ
response  ||| S:1733 E:1742 ||| NN
in  ||| S:1742 E:1745 ||| IN
single  ||| S:1745 E:1752 ||| JJ
patients ||| S:1752 E:1760 ||| NNS
.  ||| S:1760 E:1762 ||| .
